Zentalis Pharmaceuticals, Inc.’s ZNTL share price has dipped by 8.97%, which has investors questioning if this is right time ...

Researchers at Bristol University have created a lay summary for their research. The project will investigate the mechanisms of a new clinical drug combination currently in clinical trials for breast ...

On March 5, 2025, the FDA cleared an investigational new drug application for CTD402, a CD7-targeted universal CAR T-cell therapy, for the treatment of pediatric and adult patients with ...

DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) announced a key milestone in its ACESOT-1051 clinical trial, as the first patient with HPV-positive (HPV+) head and neck squamous cell ...

Aprea Therapeutics has dosed a subject with human papillomavirus (HPV)-positive head and neck squamous cell carcinoma (HNSCC) ...

Acrivon Therapeutics, Inc.’s ACRV share price has dipped by 17.24%, which has investors questioning if this is right time to buy.

A patient with HPV-positive head and neck squamous cell carcinoma was dosed in a phase 1 clinical trial evaluating APR-1051.

HPV driven cancers, including HPV+ HNSCC, are characterized by defects in the DDR pathway, making them potentially susceptible to WEE1 inhibition. HPV+ cancers are those where the underlying cause is ...

Azenosertib is a novel, selective, and orally bioavailable inhibitor of WEE1 currently being evaluated as a monotherapy and combination clinical studies in ovarian cancer and additional tumor types.

Schrödinger, Inc. (Nasdaq: SDGR) today announced that new preclinical data on SGR-3515, its investigational Wee1/Myt1 inhibitor, and SGR-4174, its SOS1 inhibitor, will be presented at the American ...

One poster demonstrating cell-free DNA molecular response as a potential surrogate endpoint to measure clinical efficacy of azenosertib in patients with high-grade serous ovarian cancer (HGSOC) Three ...

We made excellent progress across our pipeline in 2024, laying a strong foundation for the year ahead,” said Oren Gilad, Ph.D., President and Chief Executive Officer of Aprea. “We continue to enroll ...